Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen Inc    BIIB


Delayed Quote. Delayed  - 10/26 10:00:00 pm
296.46 USD   +3.66%
12:48a Lundin Law PC Announces Securities Class Action Lawsuit against B..
10/26 Goldberg Law PC Announces Securities Class Action Lawsuit against..
10/26 BIOGEN : tops Street 3Q forecasts
News SummaryMost relevantAll newsSector news 

Biogen Idec Inc. : Biogen Sees Positive Results From First Year of MS Treatment Study

share with twitter share with LinkedIn share with facebook
share via e-mail
03/20/2013 | 01:06pm CEST
   By Saabira Chaudhuri 

Biogen Idec Inc. (BIIB) said it has seen positive results from the first year of a two-year late-stage study of its investigational candidate for a type of multiple sclerosis.

Biogen said results from its two-year pivotal Phase 3 "Advance" study of Plegridy, its investigational candidate for relapsing-remitting multiple sclerosis dosed once every two weeks or every four weeks, indicate that Plegridy significantly reduced multiple sclerosis disease activity, including relapses, disability progression and brain lesions, compared with placebo at one year.

"These full first-year results provide a more complete picture of Plegridy and its positive effects on the reduction of relapse, disability progression and lesion development," said Peter Calabresi, director at the Johns Hopkins Multiple Sclerosis Center. "These data suggest that, if approved, Plegridy may offer the benefit of a less frequent dosing schedule, which would be a meaningful advance for people living with multiple sclerosis."

Plegridy--also called peginterferon beta-1a--met the primary endpoint of reducing annualized relapse rate at one year by 36% compared with placebo. It also met its secondary endpoint, reducing the proportion of patients who relapsed by 39% compared with placebo. Additionally, it significantly reduced the number of gadolinium-enhancing lesions by 86% compared with placebo.

Biogen described Plegridy as a new molecular entity in which interferon beta-1a is pegylated to extend its half-life and prolong its exposure in the body, enabling study of a less-frequent dosing schedule. The investigational drug candidate is a member of the interferon class of treatments and, if approved, would be a new addition to this class, which often is used as a first-line treatment for multiple sclerosis.

The latest announcement comes after, in January, Biogen said data from a late-stage trial of Plegridy were positive. At the time, Biogen said the study's primary endpoint was met for both the two-week and four-week dose regimens. Results showed that Plegridy also met the secondary endpoints. It noted that with both dose regimens studied the risk-benefit profile of Plegridy appears to be favorable.

Also in January, Biogen reported its fourth-quarter earnings fell 2.7% as the biotechnology company's preparations to launch a new drug for multiple sclerosis increased expenses and masked revenue growth from its existing multiple sclerosis treatment.

Shares closed Tuesday at $175.61 and were inactive in recent premarket trading. The stock has risen 47% in the past 12 months.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BIOGEN INC
12:48a Lundin Law PC Announces Securities Class Action Lawsuit against Biogen Inc. a..
10/26 BIOGEN : Management's Discussion and Analysis of Financial Condition and Results..
10/26 Goldberg Law PC Announces Securities Class Action Lawsuit against Biogen Inc...
10/26 BIOGEN : tops Street 3Q forecasts
10/26 BIOGEN INC. : Results of Operations and Financial Condition (form 8-K)
10/26 BIOGEN : Reports Record Third Quarter 2016 Revenues of $3.0 Billion
10/19 BIOGEN : Charter Trust Co Lowers stake in Biogen Inc
10/05DJPFIZER : Samsung Group Furthers Drug Push -- WSJ
10/04DJBIOGEN : Correction to Samsung BioLogics story
10/04DJBIOGEN : Samsung Affiliate Seeks European Approval for Near-Replica of Herceptin
More news
Sector news : Biopharmaceuticals
10/26 GLAXOSMITHKLINE : British imports of cheap medicines dry up as pound falls
10/26DJGlaxo Profit Jumps on Weaker Pound
10/26 Bayer third-quarter profit beats forecasts on pharma, pesticides
10/25DJMERCK : Profit Rises on Cancer Drugs, Vaccines
10/25DJMERCK : Revenue and Profit Rise on Cancer Drugs, Vaccines -- Update
More sector news : Biopharmaceuticals
News from SeekingAlpha
10/26 Biogen (BIIB) Q3 2016 Results - Earnings Call Transcript
10/26 BIOTECH FORUM DAILY DIGEST : Earnings Season Begins, Election Still Looms Large
10/26 Biogen Q3 top line up 6%; non-GAAP EPS up 16%; shares ahead 3% premarket
10/26 Biogen beats by $0.22, beats on revenue
10/25 Notable earnings before Wednesday?s open
Financials ($)
Sales 2016 11 472 M
EBIT 2016 6 067 M
Net income 2016 4 011 M
Debt 2016 1 112 M
Yield 2016 -
P/E ratio 2016 15,64
P/E ratio 2017 14,46
EV / Sales 2016 5,56x
EV / Sales 2017 5,28x
Capitalization 62 669 M
More Financials
Duration : Period :
Biogen Inc Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Full-screen chart
Technical analysis trends BIOGEN INC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 340 $
Spread / Average Target 19%
Consensus details
EPS Revisions
More Estimates Revisions
George A. Scangos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Spyridon Artavanis-Tsakonas Chief Scientific Officer & Executive VP
Adriana Karaboutis Executive VP-Technology & Business Solutions
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC-6.64%62 669
CSL LIMITED-2.64%35 725
GRIFOLS SA-13.93%12 399
More Results